tiprankstipranks

Greg Zante Insider Profile

11 Followers
Greg Zante, VP, Finance & Administration at Sangamo Therapeutics, holds 693.00 shares in Sangamo Therapeutics (Ticker: SGMO), holds 189.89K shares in Viking Therapeutics (Ticker: VKTX). Most recently, Greg Zante ― shares of Sangamo Therapeutics on ― for an estimated value of ―.
tipranks
Greg Zante

Greg Zante
Sangamo Therapeutics (SGMO)
VP, Finance & Administration

Ranked #82,979 out of 106,487 Corporate Insiders

Profitable Transactions

33%
2 out of 6 Profitable Transactions

Average Return

-17.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$6M
100.00%
<0.01%
A breakdown of Greg Zante's holdings

Insider Roles

Viking Therapeutics
(VKTX)
CFO
Sangamo Therapeutics
(SGMO)
VP, Finance & Administration
Roles that Greg Zante holds in companies

Most Profitable Insider Trade

Stock:
Viking Therapeutics
(VKTX)
Rating:Informative Sell
Date:Jul 31, 2024 - Jul 31, 2025
Return:+42.80%
The most profitable trade made by Greg Zante

Greg Zante's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Sangamo Therapeutics
VP, Finance & Administration
$177.41
Viking Therapeutics
Jan 05, 2026
CFO
Uninformative Buy
$6.40M
List of latest transactions for each holding click on a transaction to see Greg Zante's performance on stock

Greg Zante insider profile FAQ

What is the percentage of profitable transactions made by Greg Zante?
The percentage of profitable transactions made by Greg Zante is 33%.
    What is the average return per transaction made by Greg Zante?
    The average return per transaction made by Greg Zante is -17.10%.
      What stocks does Greg Zante hold?
      Greg Zante holds: SGMO, VKTX stocks.
        What was Greg Zante’s latest transaction?
        Greg Zante latest transaction was an Uninformative Buy of ―.
          What was Greg Zante's most profitable transaction?
          Greg Zante’s most profitable transaction was an Informative Sell of VKTX stock on July 31, 2024. The return on the trade was 42.80%.
            What is Greg Zante's role in Sangamo Therapeutics?
            Greg Zante's role in Sangamo Therapeutics is VP, Finance & Administration.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.